Delivery Order SPE2DB20D7066-SPE2DB26FC1PC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $1,100.49. This firm fixed-price delivery order, with an ultimate completion date of June 2, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made on...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $45,568.82 on July 14, 2025, for the supply of Naloxone 4MG Nasal in 2-count units. This competitive, firm fixed-price delivery order is scheduled for ultimate completion by August 8, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Naloxone HCl 4 mg nasal spray (2-count units) with a ceiling value of $12,536.81. This firm fixed-price delivery order is scheduled for completion by September 30, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Naloxone HCL 4 mg nasal spray in two-count units, with a ceiling value of $3,813.36. This is a firm fixed-price, non-set-aside contract with a completion date of September 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,033.92 firm fixed price delivery order for Naloxone HCL 4 mg nasal spray on October 22, 2025, with an ultimate completion date of October 23, 2025. This competitive award, which carries no set-aside designation, represents a child contract action under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's headquarters location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,799.28 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-pack units). This contract was competitively awarded with no set-aside designation and operates under a firm fixed price structure. The work is scheduled for completion by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $6,561.40 delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-spray units) on October 27, 2025, with an ultimate completion date of October 28, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,061.22 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-dose units) on October 22, 2025, with completion scheduled for October 23, 2025. This firm fixed-price contract, awarded without set-aside restrictions, represents a competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $10,635.64. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery order is issued...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB26FC1PCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a firm fixed price ceiling value of $2,998.20 and an ultimate completion date of November 10, 2025. This competitively awarded, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive portfolio with DLA encompasses a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This delivery order for naloxone—an opioid overdose reversal medication—aligns with the company's demonstrated capability to fulfill federal medical supply requirements and support healthcare programs across the defense and civilian sectors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 11/7/25 |